Patients with the most prevalent type of hepatitis C virus (HCV) infection have a substantially higher likelihood of achieving a sustained virologic response (SVR) with a triple therapy that includes an HCV protease inhibitor, a recent report confirmed. The findings validate triple therapy as the first-line treatment for genotype 1 hepatitis C (Ann Intern Med 2013;158:114-123).
Donald M. Jensen, MD, a professor of medicine and the director of the Center for Liver Diseases at the University of Chicago Medicine, said that the Annals study confirms previous research and an FDA review. “Triple therapy with a protease inhibitor is the current standard of care,” Dr. Jensen said.
After the drugs were approved in 2011, triple therapy quickly became the general practice in urban centers throughout the United States and the regimen has been adopted slowly as standard treatment throughout the rest of the country, added Paul Pockros, MD, the director, Center for Liver Diseases, Scripps Clinic, San Diego. “I think [triple therapy] is widely adopted now,” said Dr. Pockros, who was not involved in the study.